FDA Sought To Suppress Vioxx Safety Data, Sen. Grassley Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Based upon Finance Committee investigators’ interview with FDA Office of Drug Safety’s David Graham, Grassley maintains the agency delayed presentation of a study that found an increased cardiovascular risk associated with Vioxx.